FDA panel backs Seattle Genetics drug for lymphoma
SILVER SPRING, Maryland
SILVER SPRING, Maryland (Reuters) - An experimental drug from Seattle Genetics Inc garnered unanimous backing from U.S. advisers for a second type of blood cancer.
A Food and Drug Administration advisory committee voted 10-0 on Thursday to recommend accelerated approval of the drug, under the proposed trade name Adcetris, for anaplastic large cell lymphoma (ALCL).
The panel earlier unanimously approved the drug for Hodgkin's lymphoma, another relatively rare blood cancer.
The drug is meant for ALCL patients already treated for the disease. About 2,000 new cases of ALCL were diagnosed in 2010, according to the company.
The FDA usually follows the recommendations of its advisory panels and is due to make a final decision for both indications of the drug by August 30.